Neurol. praxi. 2020;21(2):159-161 | DOI: 10.36290/neu.2019.071

Treating Holmes tremor with deep brain stimulation

MUDr. Martin Nevrlý, Ph.D.1, doc. MUDr. David Krahulík, Ph.D., MBA2, MUDr. Pavel Otruba, MBA1, MUDr. Jan Bardoň1, prof. MUDr. Petr Kaňovský, CSc., FEAN1
1 Neurologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci
2 Neurochirurgická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci

Rubral tremor, also known as Holmes tremor (HT), is a relatively rare type of tremor defined as a coarse tremor, accentuated in a static position or during movement. It is usually unilateral, with bilateral involvement occurring only rarely. It occurs due to a lesion of cerebello-rubral pathways. Pharmacological therapy is difficult and, largely, ineffective. Deep brain stimulation (DBS) of the ventral intermediate (VIM) nucleus of the thalamus is a treatment option that, in some cases, can have a very good effect. A case is reported of a 38-year-old woman who, at the age of 37 years old, suffered a left cerebellar hemisphere haemorrhage with subsequent development of gross dyskinesias and ataxia of the left-sided limbs, particularly of the upper limb, diagnosed as HT. The patient was indicated to receive treatment with VIM DBS on the right side; the procedure was uneventful and had a very good effect on the tremor. HT is a relatively rare, highly disabling syndrome caused by a lesion of the cerebello-rubral pathways; however, it could be well managed with VIM DBS.

Keywords: Holmes tremor, deep brain stimulation, ventral intermediate nucleus of the thalamus.

Received: September 21, 2019; Accepted: October 16, 2019; Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nevrlý M, Krahulík D, Otruba P, Bardoň J, Kaňovský P. Treating Holmes tremor with deep brain stimulation. Neurol. praxi. 2020;21(2):159-161. doi: 10.36290/neu.2019.071.

Video

Download citation

References

  1. Ayerbe L, Ayis S, Rudd AG, Heuschmann PU, Wolfe CD. Natural history, predictors, and associations of depression 5 years after stroke: the South London Stroke Register. Stroke 2011; 42: 1907-1911. Go to original source... Go to PubMed...
  2. Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and metaanalysis. Br J Psychiatry 2013; 202: 14-21. Go to original source... Go to PubMed...
  3. Ayerbe L, Ayis S, Crichton SL, Rudd AG, Wolfe CD. Explanatory factors for the increased mortality of stroke patients with depression. Neurology 2014; 83: 2007-2012. Go to original source... Go to PubMed...
  4. Bartoli F, Lillia N, Lax A, Crocamo C, Mantero V, Carr? G, Agostoni E, Clerici M. Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat. 2013; 2013: 862978. Go to original source... Go to PubMed...
  5. Bryndziar T, Šedová P, Mikulík R. Incidence cévní mozkové příhody v Evropě - systematická review. Cesk Slov Neurol N 2017; 80/113(2): 180-189. Go to original source...
  6. Bucur M, Papagno C. A systematic review of noninvasive brain stimulation for post-stroke depression. J Affect Disord. 2018; 238: 69-78. Go to original source... Go to PubMed...
  7. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010; 56(9): 692-699. Go to original source... Go to PubMed...
  8. Hackett ML, Pickles K, Part I. frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke 2014; 9: 1017-1025. Go to original source... Go to PubMed...
  9. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008: CD003437. Go to original source...
  10. Karaiskos D, Tzavellas E, Spengos K, Vassilopoulou S, Paparrigopoulos T. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue. J Neuropsychiatry Clin Neurosci 2012; 24: 349-353. Go to original source... Go to PubMed...
  11. Kim JM, Stewart R, Lee YS, Lee HJ, Kim MC, Kim JW, Kang HJ, Bae KY, Kim SW, Shin IS, Hong YJ, Kim JH, Ahn Y, Jeong MH, Yoon JS. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018; 320(4): 350-358. Go to original source... Go to PubMed...
  12. Kutlubaev MA, Hackett ML. Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int J Stroke 2014; 9: 1026-1036. Go to original source... Go to PubMed...
  13. Meader N, Moe-Byrne T, Llewellyn A, Mitchell AJ. Screening for poststroke major depression: a meta-analysis of diagnostic validity studies. J Neurol Neurosurg Psychiatry. 2014; 85: 198-206. Go to original source... Go to PubMed...
  14. McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol. 2016; 19(10): pyw055. Go to original source... Go to PubMed...
  15. Mitchell PH, Veith RC, Becker KJ, Buzaitis A, Cain KC, Fruin M, Tirschwell D, Teri L. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke 2009; 40: 3073-3078. Go to original source... Go to PubMed...
  16. Mohr P, Melicher T, Knyt P. Vortioxetin: přehled nového antidepresiva. Psychiatr. praxi 2016; 17(1): 31-32. Go to original source...
  17. Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013; 44: 420-426. Go to original source... Go to PubMed...
  18. Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2017; 22(4): 348-362. Go to original source... Go to PubMed...
  19. Noonan K, Carey LM, Crewther SG. Meta-analyses indicate associations between neuroendocrine activation, deactivation in neurotrophic and neuroimaging markers in depression after stroke. J Stroke Cerebrovasc Dis. 2013; 22: e124-e135. Go to original source... Go to PubMed...
  20. Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother. 2017; 18(10): 1011-1017. Go to original source... Go to PubMed...
  21. Qin B, Chen H, Gao W, Zhao LB, Zhao MJ, Qin HX, Chen W, Chen L, Yang MX. Efficacy, acceptability, and tolerability of antidepressant treatments for patients with post-stroke depression: a network meta-analysis. Braz J Med Biol Res. 2018; 51(7): e7218. Go to original source... Go to PubMed...
  22. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. Am J Psychiatry. 2016; 173(3): 221-231. Go to original source... Go to PubMed...
  23. Salter KL, Foley NC, Zhu L, Jutai JW, Teasell RW. Prevention of poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis. 2013; 22(8): 1243-1251. Go to original source... Go to PubMed...
  24. Sun Y, Liang Y, Jiao Y, Lin J, Qu H, Xu J, Zhao C. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ Open. 2017; 7(8): e016499. Go to original source... Go to PubMed...
  25. Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, Jorge RE, Kissela BM, Mitchell PH, Skolarus LE, Whooley MA, Williams LS; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017; 48(2): e30-e43. Go to original source... Go to PubMed...
  26. Wei N, Yong W, Li X, Zhou Y, Deng M, Zhu H, Jin H. Post-stroke depression and lesion location: a systematic review. J Neurol. 2015; 262: 81-90. Go to original source... Go to PubMed...
  27. Williams LS, Kroenke K, Bakas T, Plue LD, Brizendine E, Tu W, Hendrie H. Care management of poststroke depression: a randomized, controlled trial. Stroke 2007; 38: 998-1003. Go to original source... Go to PubMed...
  28. Xu XM, Zou DZ, Shen LY, Liu Y, Zhou XY, Pu JC, Dong MX, Wei YD. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine (Baltimore). 2016; 95(45): e5349. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.